The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,012.00
Bid: 2,000.00
Ask: 2,004.00
Change: 18.00 (0.90%)
Spread: 4.00 (0.20%)
Open: 1,991.00
High: 2,012.00
Low: 1,969.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Pearson has positive first quarter, buys language app

Fri, 29th Apr 2022 08:25

(Alliance News) - Educational materials publisher Pearson on Friday provided a positive update on first quarter trading, while also announcing a new acquisition.

Pearson has agreed to buy Mondly, an online language learning platform. It provided no financial details, but said it expects the purchase to accelerate revenue growth for its English Language Learning division from 2023 onward. It expects mid-teens margins for the division by 2025.

"Mondly is a fast growing and profitable business that expands our reach and scale in the language learning market and drives growth for the company," said Pearson Chief Executive Andy Bird. "This acquisition is strategically important to the group as well as being accretive and driving shareholder returns."

Mondly offers learning of English and 40 other languages via its app and other digital products, including virtual reality.

Turning to its own recent trading, Pearson reported underlying sales growth of 7% in the first quarter. It reaffirmed its guidance for adjust operating profit in 2022.

Pearson added that its GBP350 million share buyback programme has begun, with GBP75 million already completed.

Pearson shares were up 2.2% early Friday.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.5% at 7,545.66

----------

Hang Seng: up 3.4% at 20,959.08

Nikkei 225: Tokyo market closed for holiday

S&P/ASX 200: closed up 1.1% at 7,435.00

----------

DJIA: closed up 614.46 points, or 1.9%, at 33,916.39

S&P 500: closed up 103.54 points, or 2.5%, at 4,287.50

Nasdaq Composite: closed up 382.59 points, or 3.1%, at 12,871.53

----------

EUR: up at USD1.0542 (USD1.0524)

GBP: up at USD1.2530 (USD1.2458)

USD: down at JPY130.29 (JPY131.00)

Gold: up at USD1,911.36 per ounce (USD1,887.75)

Oil (Brent): up at USD108.39 a barrel (USD106.55)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Friday's key economic events still to come

Japan Showa Day. Financial markets closed.

1100 CEST EU gross domestic product

1100 CEST EU consumer price index

0830 EDT US personal income & outlays

1000 EDT US University of Michigan survey of consumers

----------

Annual UK house price growth slowed slightly in April but remained robust, according to figures from mortgage lender Nationwide. UK house prices rose 12% year-on-year in April, slowing from March's 14% climb. "Nevertheless, this is the 11th time in the past 12 months that the annual growth rate has been in double digits," Nationwide analyst Robert Gardner commented. On a monthly basis, the average UK house price climbed 0.3% to GBP267,620, from GBP265,312. In March, prices had risen 1.1% monthly. Gardner added: "Housing market activity has remained solid with mortgage approvals continuing to run above pre-Covid levels. Demand is being supported by robust labour market conditions, where employment growth has remained strong and the unemployment rate has fallen back to pre-pandemic lows."

----------

Ukrainian President Volodymyr Zelensky welcomed further US financial support as a "very important step". Zelensky thanked both US President Joe Biden and the American people for their help, expressing hope that the US Congress would "quickly support" the USD33 billion boost. "President Biden rightly said today that this step is not cheap," Zelensky said in his daily video address. "But the negative consequences of Russia's aggression against Ukraine and against democracy are so large-scale for the whole world that, in comparison with them, this support from the US is necessary. Together, we can certainly stop Russian aggression and reliably defend freedom in Europe." Of the latest sum, USD20 billion would be used for military aid while USD8.5 billion would be provided for economic aid. The US has pledged or already delivered weapons and ammunition worth more than USD3.7 billion to Ukraine since Moscow's attacks began in late February.

----------

BROKER RATING CHANGES

----------

JPMorgan cuts J Sainsbury price target to 190 (230) pence - 'underweight'

----------

RBC cuts Oxford Nanopore Technologies price target to 400 (700) pence - 'outperform'

----------

COMPANIES - FTSE 100

----------

NatWest rounded off the UK blue-chip banking earnings season with a slight flourish. Total income in the three months to March 31 climbed 17% annually to GBP3.03 billion from GBP2.59 billion. Operating pretax profit jumped 96% to GBP1.25 billion from GBP635 million. The lender expects to meet annual guidance, though there is an improved outlook for its 'Go-Forward' businesses, which exclude Ulster Bank Republic of Ireland. NatWest now expects total income, excluding notable items, at the "Go-Forward" units to be "comfortably above" GBP11.0 billion. Back in February, it only expected total income "above GBP11.0 billion", not "comfortably above". In addition, on Friday, AIB said it has entered into exclusive talks with NatWest to acquire EUR6 billion in Ulster Bank performing tracker mortgages. "Any potential transaction remains subject to negotiations and agreement," AIB added.

----------

Pharmaceutical firm AstraZeneca's got a boost from its acquisition of Alexion. AstraZeneca said its total revenue in the first three months of 2022 surged 56% to USD11.39 billion. The drugmaker's reported earnings per share fell 79% yearly, however, to USD0.25. Core EPS, which excludes acquisition-related items, amortisation of intangibles, impairments, and restructuring charges, was 16% higher at USD1.89. Astra said the revenue surge reflected "growth across the company, the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete delivery by half year 2022". AstraZeneca completed its USD39 billion takeover of Boston-based rare diseases firm Alexion Pharmaceuticals in July last year. Astra backed annual guidance. It tips revenue to rise "by a high teens percentage" and core EPS to climb by a "mid-to-high twenties percentage". Both growth rates are at constant currency. Astra has not given any guidance on a reported basis. It also said it plans to launch a new R&D site in Cambridge, Massachusetts.

----------

Generic drug maker Hikma Pharmaceuticals raised guidance for its key Injectables business due to the contribution from its acquisition of Custopharm. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to USD425 million. The deal added up to 13 approved products to Hikma's portfolio. The company said it now expects Injectables revenue growth in mid-to-high single digits in 2022, up from previous guidance of low-to-mid single digits. Generics revenue is expected to grow by 8% to 10% in 2022, while Branded revenue is expected to be in line with 2021.

----------

Reckitt Benckiser reported a slight revenue fall in the first quarter of 2022 but said it expects 2022 like-for-like net revenue growth at the upper end of its 1% to 4% guidance. "Despite significant cost inflation, we expect adjusted operating margins in-line with prior year and current market expectations," the Dettol and Air Wick owner said. Net revenue in the first quarter fell 2.3% year-on-year to GBP3.42 billion. On a like-for-like basis, it was up 5.6%. Hygiene arm revenue fell 9.0% like-for-like, though Nutrition surged 20% and Health jumped 21%.

----------

Oil major BP will partner with German automaker Volkswagen to "boost" adoption of electric vehicles across Europe. The pair plans to "rapidly" build fast-charging EV network across Europe by 2024. "Volkswagen's innovative Flexpole 150,000 watts charging units, each of which features two charge points, have an integrated battery storage system, overcoming one of the biggest obstacles to the rapid roll-out of fast charging infrastructure in Europe today – the need for high-powered grid connections," VW explained. First phase of the roll-out will see up to an additional 4,000 charge points at BP's Aral retail sites in Germany and BP retail sites in the UK over the next 24 months. The paid hope to make 8,000 charge points available across Europe by end of 2024.

----------

COMPANIES - SMALL CAP

----------

Electrical goods seller AO World said it is "cautious" about its revenue and profit outlook, amid supply chain pressures and the impact of inflation. In the year ended March 31, group revenue fell 6% year-on-year, though was up 52% from two years prior. A strategic review launched in January is continuing, AO World added.

----------

Building materials company Kingspan said first-quarter revenue surged, though inflationary pressures, which had ebbed slightly at the turn of the year, have returned in recent weeks. Kingspan's revenue in the first quarter of 2022 jumped 47% year-on-year to EUR1.89 billion. "Raw material inflation which had eased considerably at the turn of the year has returned sharply over the past six weeks and the associated recovery effort is ongoing," it cautioned. "The group's trading outlook for the second quarter is positive with a strong order backlog on hand and decent activity in most end-markets. Raw material inflation remains an issue to be firmly managed, coming on the back of a highly inflationary year in 2021."

----------

COMPANIES - GLOBAL

----------

BASF said first-quarter profit was hit by Russia-related impairment charges, despite healthy growth in sales. The Ludwigshafen, Germany-based chemical company said that, in the first quarter, sales grew 19% year-on-year to EUR23.08 billion from EUR19.40 billion. This was mainly driven by higher prices, notably in the Chemicals and Materials segments, which was somewhat offset by slightly lower sales volumes, BASF said. Earnings before interest and tax rose 19% to EUR2.8 billion, but pretax profit dropped 16% to EUR1.88 billion from EUR2.25 billion in the first quarter of 2021. The drop was due to impairment charges from Wintershall Dea, which caused a decline in income from shareholdings of EUR1.1 billion. The charges were caused by the war in Ukraine, and concerned assets in Russia and the gas transportation business.

----------

Friday's shareholder meetings

ADVFN PLC - GM re director appointments

AstraZeneca PLC - AGM

BBGI Global Infrastructure SA - AGM

GreenCoat Renewables PLC - AGM

Holders Technology PLC - AGM

HSBC Holdings PLC - AGM

JPMorgan Claverhouse Investment Trust PLC - AGM

Kingspan Group PLC - AGM

Minoan Group PLC - AGM

Nostrum Oil & Gas PLC - GM - re notes restructuring

Pearson PLC - AGM

Photo-Me International PLC - AGM

Rotork PLC - AGM

Smurfit Kappa Group PLC - AGM

Travis Perkins PLC - AGM

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.